SEC Form 4 · accession 0001209191-17-056437
Niagen Bioscience, Inc. · NAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin M Farr
Officer — Chief Financial Officer
Period of report
Oct 5, 2017
Accepted (ET)
Oct 10, 2017 · 4:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001386570
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $4.24 | Oct 5, 2017 | A | 1,000,000 | A | — | Oct 4, 2027 | Common Stock | 1,000,000 | 1,000,000 | D |
Explanation of responses
- F1The number of shares subject to the option shall vest in equal monthly installments over three years such that all the shares subject to the option shall have vested on the third anniversary of October 5, 2017.